Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » In The Pipeline

    In The Pipeline

    February 1, 2004
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    In The Pipeline

    • ViaCell will begin to enroll patients in a Phase I/II clinical trial of CB001, a highly purified population of stem cells that has been isolated from umbilical cord blood and multiplied using the company’s patented Selective Amplification technology. The objective of the trial is to assess the safety of CB001 and the rate and durability of blood and immune system reconstitution using CB001 in the treatment of adult patients with advanced stages of hematologic cancers who have undergone high-dose chemotherapy and radiation treatment.

    • Stressgen Biotechnologies Corp. has announced today that the U.S. Food and Drug Administration (FDA) has designated HspE7, the company’s lead immunotherapeutic for human papillomavirus-related diseases, as a fast-track product development program for the treatment of patients suffering from recurrent respiratory papillomatosis.

    • Millennium Pharmaceuticals has announced that the FDA has granted its investigational cancer therapy, MLN2704, fast-track designation. MLN2704 currently is being evaluated in a Phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center and New York-Presbyterian Hospital/Weill Cornell Medical Center for the treatment of patients with metastatic androgen-independent prostate cancer.

    Post a comment to this article

    Report Abusive Comment

    Drug Formulary Review Archives

    View PDF
    Drug Formulary Review 2004-02-01
    February 1, 2004

    Table Of Contents

    Computer prompt promotes switch from intravenous to oral medications

    Pharmacist interventions increase dramatically with new technology

    Abbott stands firm in ritonavir price increase

    Combination drug therapy prevents BPH progression

    News Briefs

    In The Pipeline

    New FDA Appovals

    Drug Criteria & Outcomes - Alefacept (Amevive) Formulary Review

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events

    Free Email Newsletters

    All Fields Required

    E-Newsletter Options
    • Accreditation Council for Continuing Medical Education
    • American Nurses Credentialing Center
    • American College of Emergency Physician
    • American Board of Internal Medicine: Maintenance of Certification
    • California Board of Registered Nursing
    • Commission for Case Manager Certification
    • American Academy of Pediatrics
    • American Osteopathic Association
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2019 Relias. All rights reserved.

    Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing